Lumin Health, a Boston-area provider of medically supervised ketamine and insurance-covered esketamine (Spravato) treatment, has named Dr. Aakash Sathappan as site director of its Brookline, Massachusetts location. The appointment strengthens the organisation's clinical leadership bench as it expands access to interventional psychiatric care across the greater Boston region, at a moment when national demand for these therapies continues to climb.
In his new role, Dr. Sathappan will oversee day-to-day clinical operations at the Brookline outpatient centre on Beacon Street, a facility that treats adults living with treatment-resistant depression, severe anxiety, PTSD and obsessive-compulsive disorder. His responsibilities include directing patient-centred care protocols, coordinating with referring physicians and community networks, and maintaining the clinical safety standards that govern ketamine and esketamine administration.
Dr. Sathappan brings a substantial academic and clinical pedigree to the position. He completed his medical degree at the University of Kansas School of Medicine before pursuing advanced psychiatric training and fellowship work through institutions affiliated with Harvard, where he now holds an appointment as an instructor in psychiatry at Harvard Medical School. His training spans adolescent psychiatry, psychiatric consent frameworks, and intensive interventions including transcranial magnetic stimulation and electroconvulsive therapy, giving him a broad vantage point on where ketamine and esketamine fit within the wider landscape of interventional psychiatric options.
Speaking about the appointment, Dr. Sathappan noted that many of the patients who seek this kind of care have often spent years cycling through other treatments without success, frequently while feeling discouraged or overlooked by the healthcare system. He said that what matters most in his new role is building an environment where treatment is both clinically rigorous and genuinely supportive — a framing that reflects Lumin Health's broader model of pairing structured medical oversight with sustained emotional support under one roof.
The appointment arrives amid a period of accelerating national demand for interventional behavioural healthcare. FDA-approved esketamine nasal spray and intramuscular ketamine therapy are increasingly covered by insurance, drawing more patients into a category of treatment that was until recently considered a niche, cash-pay option. Yet care delivery in this space remains fragmented, often split between large hospital systems on one end and loosely regulated at-home models on the other — a gap that Lumin Health has built its business model around closing.
Lumin Health currently operates five facilities across Massachusetts and Maryland, following what the company describes as a single-site model that combines medical supervision, standardised clinical protocols and emotional support within one dedicated outpatient setting. The organisation has positioned this structure as particularly important for patients who have already exhausted multiple prior treatment approaches and are seeking a more coordinated alternative to either hospital-based or home-based ketamine therapy.
Dr. Sathappan's elevation to site director reflects a broader trend of Indian American physicians assuming clinical leadership roles within the fast-growing interventional psychiatry sector, an area of American healthcare that has expanded rapidly as insurers, regulators and patients alike have grown more comfortable with structured ketamine and esketamine protocols. For a diaspora community with a long-established presence in US medicine, his appointment adds a further data point to the community's expanding footprint in behavioural health leadership specifically, an area historically underrepresented relative to Indian Americans' broader presence in fields such as cardiology, oncology and internal medicine.
As Lumin Health continues to grow its footprint across the Northeast and Mid-Atlantic, Dr. Sathappan's dual grounding in Harvard-affiliated academic psychiatry and hands-on clinical delivery is likely to shape how the Brookline site scales its patient base while maintaining the standardised protocols the company has built its reputation on. For patients navigating treatment-resistant depression in the Boston area, his appointment signals continuity of a model designed explicitly around the gaps left by more fragmented care pathways elsewhere in the American mental healthcare system.
